| PUBLIC-AND-PRIVATE-HOSPITALS-IN-SINGAPORE |
PUBLIC-AND-PRIVATE-HOSPITALS-IN-SINGAPORE |
90%
|
We are dependent on our major customers which primarily consist of public and private hospitals in Singapore. |
| PTE-LTD |
PTE-LTD |
85%
|
Pte. Ltd., through which we gain access to Aiodine’s proprietary iodine-based technology, intellectual property, and technical expertise for the worldwide commercialization of iodine-based wound care… |
| SNNUF |
Smith & Nephew plc |
72%
|
Reciprocal relationship from SNNUF graph: Reciprocal relationship from CUPR graph: , our maggot-based chronic wound care products are subsidized under the MediSave Scheme and classified as one of the… |
| SNNUF |
Smith & Nephew plc |
72%
|
, our maggot-based chronic wound care products are subsidized under the MediSave Scheme and classified as one of the approved inpatient day surgery treatment options. Under the MediSave payment schem… |
| AIODINE-LABORATORY-PTE-LTD |
AIODINE-LABORATORY-PTE-LTD |
62%
|
actual sales of our future products that we did not anticipate prior to commercialization, which may require us to adjust our sales and marketing strategy, recruit additional personnel, or incur unfo… |
| AIODINE-PTE-LTD |
AIODINE-PTE-LTD |
62%
|
actual sales of our future products that we did not anticipate prior to commercialization, which may require us to adjust our sales and marketing strategy, recruit additional personnel, or incur unfo… |
| BEIJING-HOSPITAL-MANAGEMENT-CO-LTD |
BEIJING-HOSPITAL-MANAGEMENT-CO-LTD |
62%
|
iotech and Engineering Limited, or Advanced Biotech Primary objective We granted Advanced Biotech a sole and exclusive, non-transferable, non-sub-licensable, non-assignable, license to develop, marke… |
| BIOPHARM-UK-LTD |
BIOPHARM-UK-LTD |
62%
|
iques that have been used for centuries in many parts of the world. We modernize and advance these medical techniques based on modern medical standards and processes to improve patient outcomes and e… |
| BVI-LIMITED-INCORPORATED |
BVI-LIMITED-INCORPORATED |
62%
|
rate Law”. 27 If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business… |
| CUPRINA-CAYMAN-CUPRINA-PTE-LTD-INCORPORATED |
CUPRINA-CAYMAN-CUPRINA-PTE-LTD-INCORPORATED |
62%
|
rate Law”. 27 If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business… |
| CUPRINA-HOLDING-PTE-LTD |
CUPRINA-HOLDING-PTE-LTD |
62%
|
Cuprina Holdings (Cayman) Limited. The Reorganization has been accounted for as a recapitalization among entities under common control since the same controlling shareholder of Cuprina Holding Pte. L… |
| CUPRINA-HOLDINGS |
CUPRINA-HOLDINGS |
62%
|
Cuprina Holdings (Cayman) Limited. The Reorganization has been accounted for as a recapitalization among entities under common control since the same controlling shareholder of Cuprina Holding Pte. L… |
| CUPRINA-MENA-CO-LTD |
CUPRINA-MENA-CO-LTD |
62%
|
t events through the date that the consolidated financial statements were issued, there are no further material subsequent events that require disclosure in these consolidated financial statements ot… |
| CUPRINA-PTE-LTD |
CUPRINA-PTE-LTD |
62%
|
t events through the date that the consolidated financial statements were issued, there are no further material subsequent events that require disclosure in these consolidated financial statements ot… |
| ENGINEERING-LIMITED |
ENGINEERING-LIMITED |
62%
|
iotech and Engineering Limited, or Advanced Biotech Primary objective We granted Advanced Biotech a sole and exclusive, non-transferable, non-sub-licensable, non-assignable, license to develop, marke… |
| FERTI-CRAFT-PTE-LTD |
FERTI-CRAFT-PTE-LTD |
62%
|
iotech and Engineering Limited, or Advanced Biotech Primary objective We granted Advanced Biotech a sole and exclusive, non-transferable, non-sub-licensable, non-assignable, license to develop, marke… |
| IMARC-GROUP |
IMARC-GROUP |
62%
|
imated at USD 1.04 billion in 2026, and is expected to reach USD 1.39 billion by 2031, growing at a CAGR of 6.02% from 2026 to 2031. Mainland China is getting more requests for wound care management … |
| NAME-BACKGROUND-OWNERSHIP-CUPRINA-HOLDINGS |
NAME-BACKGROUND-OWNERSHIP-CUPRINA-HOLDINGS |
62%
|
rate Law”. 27 If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business… |
| SHANGHAI-ZHANGJIANG-YIDIANTONG-TECHNOLOGY-CO-LTD |
SHANGHAI-ZHANGJIANG-YIDIANTONG-TECHNOLOGY-CO-LTD |
62%
|
iotech and Engineering Limited, or Advanced Biotech Primary objective We granted Advanced Biotech a sole and exclusive, non-transferable, non-sub-licensable, non-assignable, license to develop, marke… |
| SKUS-CUPRINA-PTE-LTD |
SKUS-CUPRINA-PTE-LTD |
62%
|
ility by Cuprina Pte. Ltd. to manufacture IVF media product SKUs specified by Ferti-Craft, and achievement of HSA medical device registration approval for those products Arrangement between parties i… |
| WHATSAPP-GROUP |
WHATSAPP-GROUP |
62%
|
rate Law”. 27 If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business… |
| ZHEJIANG-HELIANG-TECHNOLOGY-CO-LTD |
ZHEJIANG-HELIANG-TECHNOLOGY-CO-LTD |
62%
|
ense Agreement in August 2025, the material terms of which are set out below: Parties i. Cuprina Pte. Ltd. ii. Zhejiang Heliang Technology Co., Ltd. Primary objectives Exclusive licensing and commerc… |
